All Studies Meta Analysis

Network-based multi-omics-disease-drug associations reveal drug repurposing candidates for COVID-19 disease phases

Agamah et al., ScienceOpen, doi:10.58647/DRUGARXIV.PR000010.v1

Apr 2024

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Curcumin for COVID-19

15th treatment shown to reduce risk in February 2021, now with p = 0.0000000096 from 27 studies.

Lower risk for mortality, ventilation, hospitalization, progression, recovery, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,100+ studies for 109 treatments. c19early.org

In Silico study identifying potential drugs beneficial for COVID-19 by integrating transcriptomics, proteomics, metabolomics, lipidomics, and drug data. Authors explore interactions between drugs, molecular features, and disease severity. Hypothesis-driven analysis, using IL-6 and IL-6R as seeds, highlighted immunosuppressants, corticosteroids, and IL-6 inhibitors as promising candidates, while data-driven analysis, using STAT1, SOD2, and lipid/metabolite markers as seeds, identified antioxidants, kinase inhibitors, and protein synthesis inhibitors. Network analysis revealed key hubs like CCL2, CCL4, NFKB1, and HGF that interact with drug candidates and influence disease progression. Treatments identified in the top 20 lists include ivermectin, zinc, azithromycin, indomethacin, curcumin, vitamin C, metformin, and acetylcysteine.

48 preclinical studies support the efficacy of curcumin for COVID-19:

24 In Silico studies1-24

23 In Vitro studies1,5,7,11,17,21,25-41

1 In Vivo animal study5

In Silico studies predict inhibition of SARS-CoV-2 with curcumin or metabolites via binding to the spikeA,5,10,12,18,21 (and specifically the receptor binding domainB,8,11,14), M^proC,5,7,9-11,13,14,16,19,21,22,24,38, RNA-dependent RNA polymeraseD,11,20, ACE2E,12,13,15, nucleocapsidF,6,23, nsp10G,23, and helicaseH,27 proteins. In Vitro studies demonstrate inhibition of the spikeA,32 (and specifically the receptor binding domainB,41), M^proC,17,32,38,40, ACE2E,41, and TMPRSS2I,41 proteins, and inhibition of spike-ACE2 interactionJ,25. In Vitro studies demonstrate efficacy in Calu-3K,39, A549L,32, 293TM,1, HEK293-hACE2N,17,30, 293T/hACE2/TMPRSS2O,31, Vero E6P,7,11,21,30,32,34,35,37,39, and SH-SY5YQ,29 cells. Curcumin is predicted to inhibit the interaction between the SARS-CoV-2 spike protein receptor binding domain and the human ACE2 receptor for the delta and omicron variants8, decreases pro-inflammatory cytokines induced by SARS-CoV-2 in peripheral blood mononuclear cells37, alleviates SARS-CoV-2 spike protein-induced mitochondrial membrane damage and oxidative stress1, may limit COVID-19 induced cardiac damage by inhibiting the NF-κB signaling pathway which mediates the profibrotic effects of the SARS-CoV-2 spike protein on cardiac fibroblasts42, and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity33.

Important missing comments or errors? Let us know.

Study covers ivermectin, zinc, indomethacin, curcumin, vitamin C, metformin, and N-acetylcysteine.

1. Zhang et al., Computational Discovery of Mitochondrial Dysfunction Biomarkers in Severe SARS-CoV-2 Infection: Facilitating Pytomedicine Screening, Phytomedicine, doi:10.1016/j.phymed.2024.155784.sciencedirect.com, doi.org.

2. Öztürkkan et al., In Silico investigation of the effects of curcuminoids on the spike protein of the omicron variant of SARS-CoV-2, Baku State University Journal of Chemistry and Material Sciences, 1:2, bsuj.bsu.edu.az/uploads/pdf/ec4204d62f7802de54e6092bf7860029.pdf.edu.az.

3. Yunze et al., Therapeutic effect and potential mechanism of curcumin, an active ingredient in Tongnao Decoction, on COVID-19 combined with stroke: a network pharmacology study and GEO database mining, Research Square, doi:10.21203/rs.3.rs-4329762/v1.researchsquare.com, doi.org.

4. Agamah et al., Network-based multi-omics-disease-drug associations reveal drug repurposing candidates for COVID-19 disease phases, ScienceOpen, doi:10.58647/DRUGARXIV.PR000010.v1.scienceopen.com, doi.org.

5. Boseila et al., Throat spray formulated with virucidal Pharmaceutical excipients as an effective early prophylactic or treatment strategy against pharyngitis post-exposure to SARS CoV-2, European Journal of Pharmaceutics and Biopharmaceutics, doi:10.1016/j.ejpb.2024.114279.sciencedirect.com, doi.org.

6. Hidayah et al., Bioinformatics study of curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin compounds in Curcuma longa as an antiviral agent via nucleocapsid on SARS-CoV-2 inhibition, International Conference on Organic and Applied Chemistry, doi:10.1063/5.0197724.aip.org, doi.org.

7. Singh et al., Unlocking the potential of phytochemicals in inhibiting SARS-CoV-2 M Pro protein - An in-silico and cell-based approach, Research Square, doi:10.21203/rs.3.rs-3888947/v1.researchsquare.com, doi.org.

8. Kant et al., Structure-based drug discovery to identify SARS-CoV2 spike protein–ACE2 interaction inhibitors, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2023.2300060.tandfonline.com, doi.org.

9. Naderi Beni et al., In silico studies of anti-oxidative and hot temperament-based phytochemicals as natural inhibitors of SARS-CoV-2 Mpro, PLOS ONE, doi:10.1371/journal.pone.0295014.plos.org, doi.org.

10. Moschovou et al., Exploring the Binding Effects of Natural Products and Antihypertensive Drugs on SARS-CoV-2: An In Silico Investigation of Main Protease and Spike Protein, International Journal of Molecular Sciences, doi:10.3390/ijms242115894.mdpi.com, doi.org.

11. Eleraky et al., Curcumin Transferosome-Loaded Thermosensitive Intranasal in situ Gel as Prospective Antiviral Therapy for SARS-Cov-2, International Journal of Nanomedicine, doi:10.2147/IJN.S423251.dovepress.com, doi.org.

12. Singh (B) et al., Computational studies to analyze effect of curcumin inhibition on coronavirus D614G mutated spike protein, The Seybold Report, doi:10.17605/OSF.IO/TKEXJ.ac.in, doi.org.

13. Thapa et al., In-silico Approach for Predicting the Inhibitory Effect of Home Remedies on Severe Acute Respiratory Syndrome Coronavirus-2, Makara Journal of Science, doi:10.7454/mss.v27i3.1609.ac.id, doi.org.

14. Srivastava et al., Paradigm of Well-Orchestrated Pharmacokinetic Properties of Curcuminoids Relative to Conventional Drugs for the Inactivation of SARS-CoV-2 Receptors: An In Silico Approach, Stresses, doi:10.3390/stresses3030043.mdpi.com, doi.org.

15. Alkafaas et al., A study on the effect of natural products against the transmission of B.1.1.529 Omicron, Virology Journal, doi:10.1186/s12985-023-02160-6.biomedcentral.com, doi.org.

16. Winih Kinasih et al., Analisis in silico interaksi senyawa kurkuminoid terhadap enzim main protease 6LU7 dari SARS-CoV-2, Duta Pharma Journal, doi:10.47701/djp.v3i1.2904.ac.id, doi.org.

17. Wu et al., Potential Mechanism of Curcumin and Resveratrol against SARS-CoV-2, Research Square, doi:10.21203/rs.3.rs-2780614/v1.researchsquare.com, doi.org.

18. Nag et al., Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552.sciencedirect.com, doi.org.

19. Rampogu et al., Molecular Docking and Molecular Dynamics Simulations Discover Curcumin Analogue as a Plausible Dual Inhibitor for SARS-CoV-2, International Journal of Molecular Sciences, doi:10.3390/ijms23031771.mdpi.com, doi.org.

20. Singh (C) et al., Potential of turmeric-derived compounds against RNA-dependent RNA polymerase of SARS-CoV-2: An in-silico approach, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104965.sciencedirect.com, doi.org.

21. Kandeil et al., Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2, Pathogens, doi:10.3390/pathogens10060758.mdpi.com, doi.org.

22. Rajagopal et al., Activity of phytochemical constituents of Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach, Future Journal of Pharmaceutical Sciences, doi:10.1186/s43094-020-00126-x.springeropen.com, doi.org.

23. Suravajhala et al., Comparative Docking Studies on Curcumin with COVID-19 Proteins, Preprints, doi:10.20944/preprints202005.0439.v3.preprints.org, doi.org.

24. Sekiou et al., In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2, ChemRxiv, doi:10.26434/chemrxiv.12181404.v1.chemrxiv.org, doi.org.

25. Emam et al., Establishment of in-house assay for screening of anti-SARS-CoV-2 protein inhibitors, AMB Express, doi:10.1186/s13568-024-01739-8.springeropen.com, doi.org.

26. Van Tin et al., Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF-κB Signaling, Cells, doi:10.3390/cells13161331.mdpi.com, doi.org.

27. Li et al., Thermal shift assay (TSA)-based drug screening strategy for rapid discovery of inhibitors against the Nsp13 helicase of SARS-CoV-2, Animals and Zoonoses, doi:10.1016/j.azn.2024.06.001.sciencedirect.com, doi.org.

28. Kamble et al., Nanoparticulate curcumin spray imparts prophylactic and therapeutic properties against SARS-CoV-2, Emergent Materials, doi:10.1007/s42247-024-00754-6.springer.com, doi.org.

29. Nicoliche et al., Antiviral, anti-inflammatory and antioxidant effects of curcumin and curcuminoids in SH-SY5Y cells infected by SARS-CoV-2, Scientific Reports, doi:10.1038/s41598-024-61662-7.nature.com, doi.org.

30. Nittayananta et al., A novel film spray containing curcumin inhibits SARS-CoV-2 and influenza virus infection and enhances mucosal immunity, Virology Journal, doi:10.1186/s12985-023-02282-x.biomedcentral.com, doi.org.

31. Septisetyani et al., Curcumin and turmeric extract inhibited SARS-CoV-2 pseudovirus cell entry and Spike mediated cell fusion, bioRxiv, doi:10.1101/2023.09.28.560070.biorxiv.org, doi.org.

32. Mohd Abd Razak et al., In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds, Natural Product Communications, doi:10.1177/1934578X231188861.sagepub.com, doi.org.

33. Fam et al., Channel activity of SARS-CoV-2 viroporin ORF3a inhibited by adamantanes and phenolic plant metabolites, Scientific Reports, doi:10.1038/s41598-023-31764-9.nature.com, doi.org.

34. Teshima et al., Antiviral activity of curcumin and its analogs selected by an artificial intelligence-supported activity prediction system in SARS-CoV-2-infected VeroE6 cells, Natural Product Research, doi:10.1080/14786419.2023.2194647.tandfonline.com, doi.org.

35. Leka et al., In vitro antiviral activity against SARS-CoV-2 of common herbal medicinal extracts and their bioactive compounds, Phytotherapy Research, doi:10.1002/ptr.7463.wiley.com, doi.org.

36. Goc et al., Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants, European Journal of Microbiology and Immunology, doi:10.1556/1886.2021.00022.akjournals.com, doi.org.

37. Marín-Palma et al., Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms, Molecules, doi:10.3390/molecules26226900.mdpi.com, doi.org.

38. Bahun et al., Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols, Food Chemistry, doi:10.1016/j.foodchem.2021.131594.sciencedirect.com, doi.org.

39. Bormann et al., Turmeric Root and Its Bioactive Ingredient Curcumin Effectively Neutralize SARS-CoV-2 In Vitro, Viruses, doi:10.3390/v13101914.mdpi.com, doi.org.

40. Guijarro-Real et al., Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity, Foods, doi:10.3390/foods10071503.mdpi.com, doi.org.

41. Goc (B) et al., Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions, PLOS ONE, doi:10.1371/journal.pone.0253489.plos.org, doi.org.

42. Van Tin (B) et al., Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF-κB Signaling, Cells, doi:10.3390/cells13161331.mdpi.com, doi.org.

a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.

b. The receptor binding domain is a specific region of the spike protein that binds ACE2 and is a major target of neutralizing antibodies. Focusing on the precise binding site allows highly specific disruption of viral attachment with reduced potential for off-target effects.

c. The main protease or M^pro, also known as 3CL^pro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting M^pro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.

d. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.

e. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.

f. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.

g. Non-structural protein 10 (nsp10) serves as an RNA chaperone and stabilizes conformations of nsp12 and nsp14 in the replicase-transcriptase complex, which synthesizes new viral RNAs. Nsp10 disruption may destabilize replicase-transcriptase complex activity.

h. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.

i. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.

j. The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.

k. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.

l. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.

m. 293T is a human embryonic kidney cell line that can be engineered for high ACE2 expression and SARS-CoV-2 susceptibility. 293T cells are easily transfected and support high protein expression.

n. HEK293-hACE2 is a human embryonic kidney cell line with high ACE2 expression and SARS-CoV-2 susceptibility. Cells have been transfected with a plasmid to express the human ACE2 (hACE2) protein.

o. 293T/hACE2/TMPRSS2 is a human embryonic kidney cell line engineered for high ACE2 and TMPRSS2 expression, which mimics key aspects of human infection. 293T/hACE2/TMPRSS2 cells are very susceptible to SARS-CoV-2 infection.

p. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.

q. SH-SY5Y is a human neuroblastoma cell line that exhibits neuronal phenotypes. It is commonly used as an in vitro model for studying neurotoxicity, neurodegenerative diseases, and neuronal differentiation.

Agamah et al., 16 Apr 2024, preprint, 6 authors. Contact: francisagamahh@gmail.com, peter-bram.thoen@radboudumc.nl, emile.chimusa@northumbria.ac.uk.

In Silico studies are an important part of preclinical research, however results may be very different in vivo.

This Paper Curcumin All

Network-based multi-omics-disease-drug associations reveal drug repurposing candidates for

Francis Edem Agamah, Thomas H A Ederveen, Michelle Skelton, Darren P Martin, MSc Emile R Chimusa, Peter A C 't Hoen 't Hoen, PhD Peter A C 't Hoen

Background: The development and roll-out of vaccines, and the use of various drugs have contributed to controlling the COVID-19 pandemic. Nevertheless, challenges such as the inequitable distribution of vaccines, the influence of emerging viral lineages and immune evasive variants on vaccine efficacy, and the inadequate immune defense in subgroups of the population continue to motivate the development of new drugs to combat the disease. Aim: In this study, we sought to identify, prioritize, and characterize drug repurposing candidates appropriate for treating mild, moderate, or severe COVID-19 using a network-based integrative approach that systematically integrates drug-related data and multi-omics datasets. Methods: We leveraged drug data, and multi-omics data, and used a random walk restart algorithm to explore an integrated knowledge graph comprised of three subgraphs: (i) a COVID-19 knowledge graph, (ii) a drug repurposing knowledge graph, and (iii) a COVID-19 disease-state specific omics graph. Results: We prioritized twenty FDA-approved agents as potential candidate drugs for mild, moderate, and severe COVID-19 disease phases. Specifically, drugs that could stimulate immune cell recruitment and activation including histamine, curcumin, and paclitaxel have potential utility in mild disease states to mitigate disease progression. Drugs like omacetaxine, crizotinib, and vorinostat that exhibit antiviral properties and have the potential to inhibit viral replication can be considered for mild to moderate COVID-19 disease states. Also, given the association between antioxidant deficiency and high inflammatory factors that trigger cytokine storms, antioxidants like glutathione can be considered for moderate disease states. Drugs that exhibit potent antiinflammatory effects like (i) anti-inflammatory drugs (sarilumab and tocilizumab), (ii) corticosteroids (dexamethasone and hydrocortisone), and (iii) immunosuppressives (sirolimus and cyclosporine) are potential candidates for moderate to severe disease states that trigger a hyperinflammatory cascade of COVID-19. Conclusion: Our study demonstrates that the multi-omics data-driven integrative analysis within the drug data enables prioritizing drug candidates for COVID-19 disease phases, offering a comprehensive basis for therapeutic strategies that can be brought to market quickly given their established safety profiles. Importantly, the multi-omics data-driven integrative analysis within the drug data approach implemented here can be used to prioritize drug repurposing candidates appropriate for other diseases.

Declarations Ethics approval and consent to participate Not applicable Consent for publication The authors have consented for the work to be published. Supplementary Files Supplementary data Supplementary file 1 Supplementary file 2 Supplementary file 3 Supplementary file 4 Supplementary file 5 Next, we prioritized and characterized candidate drugs followed by drug prediction robustness analysis. Finally, we concluded the analysis by validating the predicted drug candidates. Figure legends

References

Agamah, Computational approaches for network-based integrative multiomics analysis, Frontiers in Molecular Biosciences

Agamah, Network-based integrative multi-omics approach reveals biosignatures specific to COVID-19 disease phases, bioRxiv

Al-Kuraishy, Anti-histamines and Covid-19: hype or hope, JPMA J Pak Med Assoc

Alam, Czajkowsky, SARS-CoV-2 infection and oxidative stress: Pathophysiological insight into thrombosis and therapeutic opportunities, Cytokine & Growth Factor Reviews

Aoyagi, Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids, Frontiers in Medicine

Arazi, Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches

Archin, Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy, Nature

Attademo, Bernardini, Are dopamine and serotonin involved in COVID-19 pathophysiology?, The European journal of psychiatry

Bailly, Etoposide: A rider on the cytokine storm, Cytokine

Baptista, Brière, Baudot, Random Walk with Restart on multilayer networks: from node prioritisation to supervised link prediction and beyond, BMC bioinformatics

Baptista, Gonzalez, Baudot, Universal multilayer network exploration by random walk with restart, Communications Physics

Battaglia, Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance, Diabetes

Beigel, Remdesivir for the treatment of Covid-19, New England Journal of Medicine

Belli, Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study, Gastroenterology

Ben Abdallah, Twice-daily oral zinc in the treatment of patients with coronavirus disease 2019: a randomized double-blind controlled trial, Clinical Infectious Diseases

Bengtson, An open label trial to assess safety of losartan for treating worsening respiratory illness in COVID-19, Frontiers in medicine

Benucci, COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients

Benucci, COVID-19 pneumonia treated with sarilumab: a clinical series of eight patients, Journal of medical virology

Bharadwaj, SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs, Journal of Biomolecular Structure and Dynamics

Bhimraj, Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19), Clinical Infectious Diseases

Boor, Rapamycin has suppressive and stimulatory effects on human plasmacytoid dendritic cell functions, Clinical & Experimental Immunology

Bramante, Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial, The Lancet Infectious Diseases

Bustamante, Tryptophan Metabolism 'Hub'Gene Expression Associates with Increased Inflammation and Severe Disease Outcomes in COVID-19 Infection and Inflammatory Bowel Disease, International Journal of Molecular Sciences

Carlos, Histamine modulates mast cell degranulation through an indirect mechanism in a model IgE-mediated reaction, European journal of immunology

Cecchini, Cecchini ; Pono, COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment? The Pan African Medical Journal, Archives of medical research

Cengiz, Effect of oral l-Glutamine supplementation on Covid-19 treatment, Clinical nutrition experimental

Chen, Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome, Eur Respiratory Soc

Chen, Immunomodulatory and antiviral activity of metformin and its potential implications in treating coronavirus disease 2019 and lung injury, Frontiers in Immunology

Chow, Association of early aspirin use with in-hospital mortality in patients with moderate COVID-19, JAMA network open

Chowdhury, Pathak, Neuroprotective immunity by essential nutrient "Choline" for the prevention of SARS CoV2 infections: An in silico study by molecular dynamics approach, Chemical physics letters

Consortium, Repurposed antiviral drugs for Covid-19-interim WHO solidarity trial results, New England journal of medicine

Coomes, Haghbayan, Interleukin-6 in COVID-19: a systematic review and meta-analysis, Reviews in medical virology

Davies, Adlimoghaddam, Albensi, The effect of COVID-19 on NF-κB and neurological manifestations of disease, Molecular Neurobiology

Davis, Comparative toxicogenomics database (CTD): update 2021, Nucleic acids research

De Flora, Balansky, La Maestra, Antioxidants and COVID-19, Journal of preventive medicine and hygiene

Del Toro, The IntAct database: efficient access to fine-grained molecular interaction data, Nucleic acids research

Diaz, Remdesivir and mortality in patients with coronavirus disease 2019, Clinical Infectious Diseases

Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, The Lancet infectious diseases

Dryden-Peterson, Nirmatrelvir plus ritonavir for early COVID-19 in a large US health system: a population-based cohort study, Annals of internal medicine

Durante, Glutamine Deficiency Promotes Immune and Endothelial Cell Dysfunction in COVID-19, International Journal of Molecular Sciences

El Bairi, Repurposing anticancer drugs for the management of COVID-19, European Journal of Cancer

El-Tanani, Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients, Pharmaceuticals

Ennis, Tiligada, Histamine receptors and COVID-19, Inflammation Research

Eriksson, Combining hypothesis-and data-driven neuroscience modeling in FAIR workflows, Elife

Ferdinands, Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, casecontrol study

Freshour, Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts, Nucleic acids research

Gajjela, Zhou, Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling, Drug discovery today

Giamarellos-Bourboulis, Complex immune dysregulation in COVID-19 patients with severe respiratory failure, Cell host & microbe

Gordon, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature

Group, Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet

Group, Dexamethasone in hospitalized patients with Covid-19, New England Journal of Medicine

Group, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet

Gupta, Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19

Gupta, Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19, JAMA internal medicine

Guy, Rapid repurposing of drugs for COVID-19, Science

Halpin, A prospective, single-center, randomized phase 2 trial of etoposide in severe COVID-19

Hamizi, Aouidane, Belaaloui, Etoposide-based therapy for severe forms of COVID-19, Medical Hypotheses

Hammond, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, New England Journal of Medicine

Han, Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity, Cancer Immunology Research

Heskin, Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management, The Lancet

Himmelstein, Systematic integration of biomedical knowledge prioritizes drugs for repurposing, Elife

Hinkson, COVID-19 Treatment Guidelines

Horby, Effect of dexamethasone in hospitalized patients with COVID-19preliminary report, MedRxiv

Hsieh, Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence, Scientific reports

Hudzik, Nowak, Zubelewicz-Szkodzinska, Consideration of immunomodulatory actions of morphine in COVID-19-Short report, Eur Rev Med Pharmacol Sci

Ioannidis, Drkg-drug repurposing knowledge graph for covid-19

Izquierdo-Alonso, N-acetylcysteine for prevention and treatment of COVID-19: Current state of evidence and future directions, Journal of infection and public health

Jamal, Alharbi, Ahmad, Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies, Journal of Biomolecular Structure and Dynamics

Jennings, Parks, Curcumin as an antiviral agent, Viruses

Johnson, Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis, The Journal of Immunology

Jones, Hunter, Is IL-6 a key cytokine target for therapy in COVID-19?, Nature Reviews Immunology

Jung, Random walk with restart on large graphs using block elimination, ACM Transactions on Database Systems (TODS)

Jørgensen, Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production, Scandinavian journal of immunology

Karsulovic, mTORC inhibitor Sirolimus deprograms monocytes in "cytokine storm" in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis-like syndrome, Clinical Immunology

Khaledi, COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy, Frontiers in medicine

Khalili, Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19, Journal of medical virology

Kim, Serious Clinical Outcomes of COVID-19 Related to Acetaminophen or NSAIDs from a Nationwide Population-Based Cohort Study, International Journal of Environmental Research and Public Health

Kim, The architecture of SARS-CoV-2 transcriptome, Cell

Kocks, A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study, ERJ Open Research

Laforge, Tissue damage from neutrophil-induced oxidative stress in COVID-19, Nature Reviews Immunology

Laing, A dynamic COVID-19 immune signature includes associations with poor prognosis, Nature medicine

Lau, Real-world COVID-19 vaccine effectiveness against the Omicron BA. 2 variant in a SARS-CoV-2 infection-naive population, Nature medicine

Li, Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV, Aids

Liew, SARS-CoV-2 neutralizing antibody bebtelovimab-a systematic scoping review and meta-analysis, Frontiers in Immunology

Liu, DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy, Nucleic acids research

Lucas, Longitudinal analyses reveal immunological misfiring in severe COVID-19, Nature

Lv, Efficient processing node proximity via random walk with restart

Ma, Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis, European Journal of Clinical Pharmacology

Ma, Homo-harringtonine, highly effective against coronaviruses, is safe in treating COVID-19 by nebulization, Science China Life Sciences

Mahdian, Ebrahim-Habibi, Zarrabi, Drug repurposing using computational methods to identify therapeutic options for COVID-19, Journal of Diabetes & Metabolic Disorders

Malone, COVID-19: famotidine, histamine, mast cells, and mechanisms, Frontiers in Pharmacology

Manjani, Effects of acetaminophen on outcomes in patients hospitalized with COVID-19, Chest

Mashauri, Covid-19 Histamine theory: Why antihistamines should be incorporated as the basic component in Covid-19 management?, Health Science Reports

Menni, COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study, The Lancet Infectious Diseases

Mirjalili, Does Losartan reduce the severity of COVID-19 in hypertensive patients?, BMC Cardiovascular Disorders

Mushtaq, Tocilizumab in critically ill COVID-19 patients: An observational study, International Immunopharmacology

Nair, Sharma, Tiwary, Glutathione deficiency in COVID19 illnessdoes supplementation help?, Saudi Journal of Anaesthesia

Nevalainen, Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial, Nature Communications

Nguyen, Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses, Science Advances

Organization, The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19

Overmyer, Large-scale multi-omic analysis of COVID-19 severity, Cell systems

Panda, Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV2 Infection

Pashmforosh, Possible Benefits of Paclitaxel Therapy for COVID-19, Pharmaceutical and Biomedical Research

Patel, Azithromycin for mild-to-moderate COVID-19, The Lancet Respiratory Medicine

Pathania, Fenizia, Cyclosporine a inhibits viral infection and release as well as cytokine production in lung cells by three SARS-CoV-2 variants, Microbiology Spectrum

Patocka, Rapamycin: drug repurposing in SARS-CoV-2 infection, Pharmaceuticals

Pektaş, Gürsoy, Demirbilek, The use of pregabalin in Intensive Care Unit in the treatment of Covid-19-related pain and cough

Perreau, The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients, Nature Communications

Puskarich, Efficacy of losartan in hospitalized patients with COVID-19induced lung injury: a randomized clinical trial, JAMA Network Open

Páez-Franco, Metabolomics analysis reveals a modified amino acid metabolism that correlates with altered oxygen homeostasis in COVID-19 patients, Scientific reports

Ravichandran, An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients, Scientific reports

Ravid, Leiva, Chitalia, Janus kinase signaling pathway and its role in COVID-19 inflammatory, vascular, and thrombotic manifestations, Cells

Rheingold, Zinc Supplementation Associated With a Decrease in Mortality in COVID-19 Patients: A Meta-Analysis, Cureus

Rincon-Arevalo, Altered increase in STAT1 expression and phosphorylation in severe COVID-19, European Journal of Immunology

Ripamonti, HDAC inhibition as potential therapeutic strategy to restore the deregulated immune response in severe COVID-19, Frontiers in immunology

Sajgure, Safety and efficacy of mycophenolate in COVID-19: A nonrandomised prospective study in western India, The Lancet Regional Health-Southeast Asia

Salerni, Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed, Molecular cancer therapeutics

Salt, Palmer, Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation, Expert opinion on investigational drugs

Samaee, Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease, International immunopharmacology

Samuel, Varghese, Büsselberg, Therapeutic potential of metformin in COVID-19: reasoning for its protective role, Trends in microbiology

Schoot, Immunosuppressive drugs and COVID-19: a review, Frontiers in pharmacology

Schwartz, Does ivermectin have a place in the treatment of mild Covid-19? New microbes and new infections

Singh, A comparative study of 5-fluorouracil, doxorubicin, methotrexate, paclitaxel for their inhibition ability for Mpro of nCoV: Molecular docking and molecular dynamics simulations, Journal of the Indian Chemical Society

Sivapalasingam, Efficacy and safety of sarilumab in hospitalized patients with coronavirus disease 2019: a randomized clinical trial, Clinical Infectious Diseases

Sosa, A literature-based knowledge graph embedding method for identifying drug repurposing opportunities in rare diseases

Sperry, Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology

Sterne, Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, Jama

Su, Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19, Cell

Suresh, Therapeutic potential of curcumin in ARDS and COVID-19, Clinical and Experimental Pharmacology and Physiology

Suriawinata, Mehta, Iron and iron-related proteins in COVID-19, Clinical and Experimental Medicine

Szklarczyk, The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets, Nucleic acids research

Takimoto, Anticancer drug development at the US National Cancer Institute, Cancer chemotherapy and pharmacology

Tanaka, Narazaki, Kishimoto, Interleukin (IL-6) immunotherapy, Cold Spring Harbor perspectives in biology

Teixeira, Simvastatin downregulates the SARS-CoV-2-induced inflammatory response and impairs viral infection through disruption of lipid rafts, Frontiers in Immunology

Telenti, After the pandemic: perspectives on the future trajectory of COVID-19, Nature

Thangam, The role of histamine and histamine receptors in mast cellmediated allergy and inflammation: the hunt for new therapeutic targets, Frontiers in immunology

Tomazou, Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in bioinformatics

Vahedian-Azimi, Effectiveness of curcumin on outcomes of hospitalized COVID-19 patients: A systematic review of clinical trials, Nutrients

Valle, An inflammatory cytokine signature predicts COVID-19 severity and survival, Nature medicine

Vitiello, Porta, Ferrara, Correlation between the use of statins and COVID-19: what do we know?, BMJ Evidence-Based Medicine

Wang, Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study, Journal of chemical information and modeling

Wang, Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response, Journal for Immunotherapy of Cancer

Weisberg, Repurposing of kinase inhibitors for treatment of COVID-19, Pharmaceutical research

Wishart, DrugBank 5.0: a major update to the DrugBank database for 2018, Nucleic acids research

Wróblewska, The Role of Glutathione in Selected Viral Diseases, Antioxidants

Wu, The SARS-CoV-2 induced targeted amino acid profiling in patients at hospitalized and convalescent stage, Bioscience Reports

Xiu, Fludarabine inhibits type I interferon-induced expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2, Cellular & Molecular Immunology

Xu, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, The Lancet respiratory medicine

Xu, Ribavirin treatment for critically ill COVID-19 patients: An observational study, Infection and Drug Resistance

Zarkovic, Post-mortem findings of inflammatory cells and the association of 4-hydroxynonenal with systemic vascular and oxidative stress in lethal COVID-19, Cells

Zhang, Immune evasive effects of SARS-CoV-2 variants to COVID-19 emergency used vaccines, Frontiers in Immunology

Zhou, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The lancet

Zhou, Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell discovery

Zhou, Role of AMP-activated protein kinase in mechanism of metformin action, The Journal of clinical investigation

Zhou, The role of SARS-CoV-2-mediated NF-κB activation in COVID-19 patients, Hypertension Research

Žarković, The impact of severe COVID-19 on plasma antioxidants, Molecules

{ 'institution': [{'name': 'ScienceOpen'}], 'indexed': {'date-parts': [[2024, 4, 18]], 'date-time': '2024-04-18T02:13:26Z', 'timestamp': 1713406406464}, 'posted': {'date-parts': [[2024, 4, 16]]}, 'reference-count': 0, 'publisher': 'ScienceOpen', 'license': [ { 'start': { 'date-parts': [[2024, 4, 16]], 'date-time': '2024-04-16T00:00:00Z', 'timestamp': 1713225600000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'funder': [ {'name': 'Dutch Organization of Scientific Research', 'award': ['184.034.019']}, {'name': 'European Union to the EATRIS-Plus infrastructure project', 'award': ['871096']}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': ' \n' ' Background:The development and roll-out of ' 'vaccines, and the use of various drugs have contributed to controlling the COVID-19 pandemic. ' 'Nevertheless, challenges such as the inequitable distribution of vaccines, the influence of ' 'emerging viral lineages and immune evasive variants on vaccine efficacy, and the inadequate ' 'immune defense in subgroups of the population continue to motivate the development of new ' 'drugs to combat the disease.\n' ' \n' ' Aim:In this study, we sought to identify, ' 'prioritize, and characterize drug repurposing candidates appropriate for treating mild, ' 'moderate, or severe COVID-19 using a network-based integrative approach that systematically ' 'integrates drug-related data and multi-omics datasets.\n' ' \n' ' Methods: We leveraged drug data, and multi-omics ' 'data, and used a random walk restart algorithm to explore an integrated knowledge graph ' 'comprised of three sub-graphs: (i) a COVID-19 knowledge graph, (ii) a drug repurposing ' 'knowledge graph, and (iii) a COVID-19 disease-state specific omics graph.\n' ' \n' ' Results:We prioritized twenty FDA-approved agents ' 'as potential candidate drugs for mild, moderate, and severe COVID-19 disease phases. ' 'Specifically, drugs that could stimulate immune cell recruitment and activation including ' 'histamine, curcumin, and paclitaxel have potential utility in mild disease states to mitigate ' 'disease progression. Drugs like omacetaxine, crizotinib, and vorinostat that exhibit ' 'antiviral properties and have the potential to inhibit viral replication can be considered ' 'for mild to moderate COVID-19 disease states. Also, given the association between antioxidant ' 'deficiency and high inflammatory factors that trigger cytokine storms, antioxidants like ' 'glutathione can be considered for moderate disease states. Drugs that exhibit potent ' 'anti-inflammatory effects like (i) anti-inflammatory drugs (sarilumab and tocilizumab), (ii) ' 'corticosteroids (dexamethasone and hydrocortisone), and (iii) immunosuppressives (sirolimus ' 'and cyclosporine) are potential candidates for moderate to severe disease states that trigger ' 'a hyperinflammatory cascade of COVID-19.\n' ' \n' ' Conclusion:Our study demonstrates that the ' 'multi-omics data-driven integrative analysis within the drug data enables prioritizing drug ' 'candidates for COVID-19 disease phases, offering a comprehensive basis for therapeutic ' 'strategies that can be brought to market quickly given their established safety profiles. ' 'Importantly, the multi-omics data-driven integrative analysis within the drug data approach ' 'implemented here can be used to prioritize drug repurposing candidates appropriate for other ' 'diseases.', 'DOI': '10.58647/drugarxiv.pr000010.v1', 'type': 'posted-content', 'created': {'date-parts': [[2024, 4, 17]], 'date-time': '2024-04-17T13:50:17Z', 'timestamp': 1713361817000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Network-based multi-omics-disease-drug associations reveal drug repurposing candidates for ' 'COVID-19 disease phases', 'prefix': '10.58647', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2980-1392', 'authenticated-orcid': False, 'given': 'Francis Edem', 'family': 'Agamah', 'sequence': 'first', 'affiliation': [ { 'id': [ { 'id': 'https://ror.org/03p74gp79', 'id-type': 'ROR', 'asserted-by': 'publisher'}], 'name': 'Computational Biology Division, Department of Integrative ' 'Biomedical Sciences, Institute of Infectious Disease and ' 'Molecular Medicine, Faculty of Health Sciences, University of ' 'Cape Town, Cape Town, South Africa'}]}, { 'given': 'Thomas H.A.', 'family': 'Ederveen', 'sequence': 'additional', 'affiliation': [ { 'id': [ { 'id': 'https://ror.org/05wg1m734', 'id-type': 'ROR', 'asserted-by': 'publisher'}], 'name': 'Department of Medical BioSciences, Radboud University Medical ' 'Center Nijmegen, The Netherlands'}]}, { 'given': 'Michelle', 'family': 'Skelton', 'sequence': 'additional', 'affiliation': [ { 'id': [ { 'id': 'https://ror.org/03p74gp79', 'id-type': 'ROR', 'asserted-by': 'publisher'}], 'name': 'Computational Biology Division, Department of Integrative ' 'Biomedical Sciences, Institute of Infectious Disease and ' 'Molecular Medicine, Faculty of Health Sciences, University of ' 'Cape Town, Cape Town, South Africa'}]}, { 'given': 'Darren P.', 'family': 'Martin', 'sequence': 'additional', 'affiliation': [ { 'id': [ { 'id': 'https://ror.org/03p74gp79', 'id-type': 'ROR', 'asserted-by': 'publisher'}], 'name': 'Computational Biology Division, Department of Integrative ' 'Biomedical Sciences, Institute of Infectious Disease and ' 'Molecular Medicine, Faculty of Health Sciences, University of ' 'Cape Town, Cape Town, South Africa'}]}, { 'given': 'Emile R.', 'family': 'Chimusa', 'sequence': 'additional', 'affiliation': [ { 'id': [ { 'id': 'https://ror.org/049e6bc10', 'id-type': 'ROR', 'asserted-by': 'publisher'}], 'name': 'Department of Applied Science, Faculty of Health and Life ' 'Sciences, Northumbria University, Newcastle, Tyne and Wear, NE1 ' '8ST, UK'}]}, { 'given': "Peter A.C. 't Hoen", 'family': "'t Hoen", 'sequence': 'additional', 'affiliation': [ { 'id': [ { 'id': 'https://ror.org/05wg1m734', 'id-type': 'ROR', 'asserted-by': 'publisher'}], 'name': 'Department of Medical BioSciences, Radboud University Medical ' 'Center Nijmegen, The Netherlands'}]}], 'member': '5403', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647/DRUGARXIV.PR000010.v1', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 4, 17]], 'date-time': '2024-04-17T13:50:18Z', 'timestamp': 1713361818000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647/DRUGARXIV.PR000010.v1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 4, 16]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.58647/DRUGARXIV.PR000010.v1', 'relation': {}, 'subject': [], 'published': {'date-parts': [[2024, 4, 16]]}, 'subtype': 'preprint'}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0